FDA Approves Otsuka's Simtriyo (Centanafadine) for ADHD Treatment

The U.S. Food and Drug Administration (FDA) has approved Simtriyo (centanafadine), Otsuka Pharmaceutical's once-daily, extended-release formulation, for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and children. The approval was granted on July 24, 2026, and was reported on July 28, 2026. Simtriyo is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), offering a distinct mechanism of action from existing ADHD therapies.

Context

ADHD is a common neurodevelopmental disorder affecting both children and adults. Existing treatments primarily focus on stimulant medications, which may not be suitable for all patients due to side effects or contraindications. The FDA's approval of a new class of medication is a notable development in the landscape of ADHD management.

Why it matters

The approval of Simtriyo represents a significant advancement in ADHD treatment options, particularly as it introduces a novel mechanism of action. This could provide relief for patients who have not responded well to traditional therapies. Additionally, the once-daily dosing may improve adherence to treatment regimens.

Implications

The introduction of Simtriyo could lead to improved outcomes for individuals with ADHD, especially those who have struggled with existing treatments. Insurance coverage and accessibility will play crucial roles in determining its impact on patient populations. If successful, this may encourage further research and development of innovative ADHD therapies.

What to watch

Healthcare providers may begin integrating Simtriyo into their treatment plans for ADHD patients in the coming months. Observations on the drug's effectiveness and side effects in real-world settings will be important. The response from patients and caregivers regarding this new option will also be closely monitored.